"Nausea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Descriptor ID |
D009325
|
| MeSH Number(s) |
C23.888.821.712
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nausea".
Below are MeSH descriptors whose meaning is more specific than "Nausea".
This graph shows the total number of publications written about "Nausea" by people in this website by year, and whether "Nausea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 4 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 5 | 6 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nausea" by people in Profiles.
-
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024 Sep 26; 391(12):1159-1162.
-
Low Vitamin D Levels in Patients with Symptoms of Gastroparesis: Relationships with Nausea and Vomiting, Gastric Emptying and Gastric Myoelectrical Activity. Dig Dis Sci. 2024 Aug; 69(8):2904-2915.
-
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584.
-
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023 10; 37(10):2017-2026.
-
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023 09; 12(17):17981-17992.
-
Relationships among intragastric meal distribution during gastric emptying scintigraphy, water consumption during water load satiety testing, and symptoms of gastroparesis. Am J Physiol Gastrointest Liver Physiol. 2023 11 01; 325(5):G407-G417.
-
Many pediatric patients with gastroparesis do not receive dietary education. BMC Gastroenterol. 2023 Jul 17; 23(1):240.
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
-
Gastrointestinal Symptoms Profile in Gastroparesis Compared to Other Functional and Organic Gastrointestinal Diseases. J Pediatr Gastroenterol Nutr. 2023 07 01; 77(1):e1-e7.
-
Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. Curr Oncol Rep. 2023 06; 25(6):569-587.